BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ogasawara N, Saitoh S, Akuta N, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H. Long‐term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus‐related liver cirrhosis after interferon‐based therapy. Hepatol Res 2019;49:1441-50. [DOI: 10.1111/hepr.13418] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Negro F. Residual risk of liver disease after hepatitis C virus eradication. J Hepatol 2021;74:952-63. [PMID: 33276027 DOI: 10.1016/j.jhep.2020.11.040] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Yongpisarn T, Thimphitthaya C, Laoveeravat P, Wongjarupong N, Chaiteerakij R. Non-invasive tests for predicting liver outcomes in chronic hepatitis C patients: A systematic review and meta-analysis. World J Hepatol 2021; 13(8): 949-968 [PMID: 34552701 DOI: 10.4254/wjh.v13.i8.949] [Reference Citation Analysis]
3 Ogasawara N, Saitoh S, Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Kumada H. Advantage of liver stiffness measurement before and after direct‐acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C. Hepatol Res 2020;50:426-38. [DOI: 10.1111/hepr.13467] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
4 Nagaoki Y, Imamura M, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Hayes CN, Chayama K, Aikata H. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients. Hepatol Res 2020;50:1222-33. [PMID: 32767446 DOI: 10.1111/hepr.13554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Cuesta-Sancho S, Márquez-Coello M, Illanes-Álvarez F, Márquez-Ruiz D, Arizcorreta A, Galán-Sánchez F, Montiel N, Rodriguez-Iglesias M, Girón-González JA. Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. World J Hepatol 2022; 14(1): 62-79 [DOI: 10.4254/wjh.v14.i1.62] [Reference Citation Analysis]
6 Ohya K, Imamura M, Teraoka Y, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Mori N, Takaki S, Tsuji K, Aisaka Y, Ishitobi T, Katamura Y, Kodama H, Nabeshima Y, Masaki K, Honda Y, Moriya T, Kohno H, Kohno H, Chayama K. Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis. Hepatol Res 2020;50:1234-43. [PMID: 32914512 DOI: 10.1111/hepr.13555] [Reference Citation Analysis]
7 Tamaki N, Kurosaki M, Higuchi M, Kirino S, Inada K, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Izumi N. Validation of albumin, bilirubin, and platelet criteria for avoiding screening endoscopy in patients with advanced fibrosis. Hepatol Res 2020;50:996-9. [PMID: 32515534 DOI: 10.1111/hepr.13533] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Ogasawara N, Saitoh S, Suzuki F, Kinowaki K, Masuda J, Denpou H, Akuta N, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Miura Y, Takano T, Kumada H. Undifferentiated carcinoma of the liver demonstrated by contrast-enhanced ultrasonography. Clin J Gastroenterol 2020;13:1225-32. [PMID: 32651870 DOI: 10.1007/s12328-020-01180-x] [Reference Citation Analysis]
9 Asahina Y; Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. JSH Guidelines for the Management of Hepatitis C Virus Infection, 2019 Update; Protective Effect of Antiviral Therapy against Hepatocarcinogenesis. Hepatol Res 2020;50:775-90. [DOI: 10.1111/hepr.13501] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
10 Cheng CH, Chu CY, Chen HL, Lin IT, Wu CH, Lee YK, Hu PJ, Bair MJ. Direct-acting antiviral therapy of chronic hepatitis C improves liver fibrosis, assessed by histological examination and laboratory markers. J Formos Med Assoc 2021;120:1259-68. [PMID: 33339709 DOI: 10.1016/j.jfma.2020.11.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]